Press Releases

 
Press Releases
  Date Title View
Oct 9, 2002
Sep 9, 2003
Sep 12, 2003
SAN DIEGO, CA, September 12, 2003 - Chimerix Inc., an emerging biotechnology company developing orally available, targeted medicines from bioactive molecules, today announced that it has licensed rights from Gilead Sciences, Inc. (Nasdaq: GILD) to develop oral derivatives of Gilead's proprietary antiviral compound cidofovir, int...
Mar 11, 2004
SAN DIEGO, CA, March 11, 2004 - Chimerix Inc., a biotechnology company developing orally available, targeted medicines for the treatment of smallpox, multi-drug resistant HIV and hepatitis virus infections, today announced that it has been awarded a Phase I Small Business Innovation Research (SBIR) grant under the Advanced Techn...
Apr 27, 2004
SAN DIEGO, CA, April 27, 2004 – Chimerix, Inc. and the University of California, San Diego (UCSD) announced today the issuance of U.S. Patent No. 6,716,825 entitled “Phosphonate Compounds” by the U.S. Patent and Trademark Office. The patent claims novel phosphonate and phosphonate-containing compounds, methods ...
Nov 4, 2004
SAN DIEGO, CA, November 4, 2004 - Chimerix Inc., an emerging biotechnology company developing orally available antiviral therapeutics, today announced an $11 million private placement of its Series C preferred stock. Frazier Healthcare Ventures, a new investor, led the round, and Robert Overell, Ph.D., a general partner with Fra...
May 12, 2005
SAN DIEGO, CA, May 12, 2005 - Chimerix Inc., an emerging biotechnology company developing orally available antiviral therapeutics, today announced that it has been named one of the Red Herring 100 Private Companies of North America.  Chimerix was chosen as one of the top emerging biotechnology companies for the company̵...
Nov 3, 2005
Nov 10, 2005
RESEARCH TRIANGLE PARK, NC, March 28, 2013 – Chimerix, Inc., a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced presentations related to the use of its broad spectrum antiviral compound CMX001 at the European Group for Blood and Marrow Transplantation's (EBMT)...
Apr 18, 2006
RESEARCH TRIANGLE PARK, NC, April 18, 2006 - Chimerix, Inc., a biotechnology company developing orally available, targeted medicines to treat smallpox and other viral infections, announced today that it has signed a Cooperative Research and Development Agreement (CRADA) with the United States Army Medical Research Institute of I...
Page:
1
... NextLast
= add release to Briefcase